A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
Inclusion Criteria:
Subject has at least a 6 month history of migraine (with or without aura) and including the following:
14 or less headache days per month during the 3 month period prior to the Screening Visit
6 or more migraine days during the Observation Period
14 or less headache days during the Observation Period
Pediatric Migraine Disability Assessment Scale (PedMIDAS) Disability Score of >10 to ≤50, indicating mild (score of 11 to 30) or moderate (score of 31 to 50) disruption in daily activities, as assessed at the Baseline (Randomization) Visit
Ability to verbally distinguish migraine attacks from tension/cluster or other types of headaches
Migraine attacks, on average, lasting 4 - 72 hours if untreated
Subjects on prophylactic migraine medication are permitted to remain on therapy if the dose has been stable for at least 3 months (12 weeks) prior to the Screening Phase, and the dose is not expected to change during the course of the study. 2) Male and female subjects ≥ 6 to <18 years; subjects must be less than 18 at the time of signing assent / consent.
3)Subjects must have a weight of ≥40 kg (child cohort requirement ≥15 kg) at the Screening Visit.
Exclusion Criteria:
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Colorado Springs, Colorado 80907, United States
Washington D.C., District of Columbia 20016, United States
Edgewater, Florida 32132, United States
Sandy Springs, Georgia 30328, United States
Columbia, Missouri 65212, United States
Columbia, Missouri 65212, United States
Amherst, New York 14226, United States
Fayetteville, North Carolina 28303, United States
Sioux Falls, South Dakota 57105, United States
Sioux Falls, South Dakota 57110, United States
Nashville, Tennessee 37232, United States
McAllen, Texas 78503, United States
Vancouver, British Columbia V6H 3V4, Canada
Latina, Latina/lazio 04100, Italy
Kasuga-shi, Fukuoka 816-0802, Japan
Kiryu-shi, Gunma 376-0035, Japan
Higashinada-ku Kobe-shi, Hyōgo 658-0064, Japan
Nishinomiya-shi, Hyōgo 663-8204, Japan
Taihaku-ku Sendai-shi, Miyagi 982-0014, Japan
Abeno-ku Osaka-shi, Osaka 545-0053, Japan
Naniwa-ku, Osaka 556-0015, Japan
Chuo-ku Saitama-shi, Saitama 338-8577, Japan
Shibuya-ku, Tokyo 151-0051, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Poznan, Greater Poland Voivodeship 61-731, Poland
Krakow, Lesser Poland Voivodeship 31-503, Poland
Wroclaw, Lower Silesian Voivodeship 52-210, Poland
Katowice, Silesian Voivodeship 40-123, Poland
Valladolid, Castille and León 47003, Spain